Prenatal Diagnosis · 1997 · 267 citations · 9 references
MedicineMaternal HealthObstetricsObstetric UltrasoundPrenatal DiagnosisUltrasonographyDown SyndromeFetal Anomaly DetectionFirst-trimester UltrasoundPrenatal Genetic DiagnosisPrenatal ImagingPrenatal Risk AssessmentBiochemical Screening MarkersFirst Trimester UltrasonographyMaternal Age EffectsNuchal Translucency ScreeningPrenatal Diagnosis Of Down SyndromePrenatal ScreeningPrenatal Screening MarkersUltrasound Markers For Genetic Disorders
The study evaluated the performance of combined ultrasound and biochemical markers for prenatal Down's syndrome screening between 10 and 14 weeks. The authors pooled three published datasets—nuchal translucency measurements and serum markers—from 86 Down's syndrome pregnancies, 77 affected and 385 unaffected pregnancies, and 561 unaffected pregnancies to assess screening performance. Combining serum markers with nuchal translucency at 10–14 weeks achieved an 80 % detection rate at a 5 % false‑positive rate, outperforming maternal‑age‑based approaches and second‑trimester serum screening.
Data on pregnancies with and without Down's syndrome between 10 and 14 weeks of pregnancy were used to determine the performance of combined ultrasound and biochemical markers in prenatal screening for Down's syndrome. We used three datasets: one published by Pandya et al. (1995) on nuchal translucency measurement in 86 Down's syndrome pregnancies; one published by Wald et al. (1996a) on free beta human chorionic gonadotrophin (hCG) and pregnancy-associated plasma protein A (PAPP-A) in 77 affected pregnancies and 385 unaffected pregnancies; and the third from Schuchter et al. on 561 unaffected pregnancies with nuchal translucency measurement. Combining the data from these three datasets showed that screening between 10 and 14 weeks by combining the serum markers with nuchal translucency measurement had a detection rate of 80 per cent for a 5 per cent false-positive rate, better than maternal age with two serum markers (62 per cent for 5 per cent) or maternal age with nuchal translucency measurement (63 per cent for 5 per cent). At this time in pregnancy, it appears that screening using the combined test is better than second-trimester serum screening (76 per cent for 5 per cent), though these estimates do not allow for any association between the markers and spontaneous fetal loss, an issue that needs to be clarified by further research. Meanwhile, these results provide a reasonable working estimate of screening performance using different combinations of these markers.
9
Maternal serum screening for Down's syndrome in early pregnancy.
N J Wald, Howard Cuckle, J. W. Densem et al. · BMJ · 1988 · 974 citations · Full text
PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN-A AS A SERUM MARKER
Nicholas Wald, JAMES W. DENSEM, Lynne M. George et al. · Prenatal Diagnosis · 1996 · 232 citations
Medicine, Endocrinology, Obstetrics +17